We Claim:

1. An induced pluripotent stem cell comprising a reprogrammed human kidney-derived cell wherein the human kidney-derived cell is positive for the expression of HLA-I and CD 44 and at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eya1, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5; and negative for the expression of CD133 and E-cadherin and at least one of Sox2, FGF4, hTert, Wnt-4, SIX2 or GATA-4.
2. The induced pluripotent stem cell of claim 1, wherein the induced pluripotent stem cell expresses TRA1-60, TRA1-81, SSEA3, SSEA4, and NANOG.
3. The induced pluripotent stem cell of claim 1, wherein the induced pluripotent stem cell is positive for alkaline phosphatase staining.
4. The induced pluripotent stem cell of claim 1, wherein the induced pluripotent stem cell differentiates into cells of an ectoderm, mesoderm, and endoderm lineages.
5. The induced pluripotent stem cell of claim 1, wherein the induced pluripotent stem cell differentiates into a hepatocyte cell, a hematoendothelial cell, and a definitive endoderm cell.
6. An induced pluripotent stem cell prepared by a method comprising the steps of:
providing a human kidney-derived cell, wherein the human kidney-derived cell is positive for the expression of HLA-I and CD 44 and at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eya1, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5; and negative for the expression of CD133 and E-cadherin and at least one of Sox2, FGF4, hTert, Wnt-4, SIX2 or GATA-4
transfecting the human kidney derived-cell with each one of a VSVg murine retrovirus expressing human transcription factor OCT4, a VSVg murine retrovirus expressing human transcription factor SOX2, a VSVg murine retrovirus expressing human transcription factor KLF4, and a VSVg murine retrovirus expressing human transcription factor c-MYC,
culturing the transfected human kidney-derived cell,

identifying an induced pluripotent stem cell,
isolating the human kidney-derived IPS cell,
subculturing the induced pluripotent stem cell, and
providing an induced pluripotent stem cell.

7. The method of claim 6, further transfecting the human kidney-derived cell with a VSVg murine retrovirus expressing human transcription factor p53-shRNA.
8. An induced pluripotent stem cell prepared by a method comprising the steps of: providing a human kidney-derived cell, transfecting the human kidney-derived cells with each one of an mRNA encoding a Oct-4 protein, an mRNA encoding a Sox2 protein, an mRNA encoding a Klf4 protein, an mRNA encoding a c-myc protein, and an mRNA encoding a Lin28 protein,
culturing the transfected human kidney-derived iPS cell,
identifying a induced pluripotent stem cell,
isolating the induced pluripotent stem cell,
subculturing the induced pluripotent stem cell, and
providing an induced pluripotent stem cell.

We Claim:

1. An induced pluripotent stem cell comprising a reprogrammed human kidney-derived cell wherein the human kidney-derived cell is positive for the expression of HLA-I and CD 44 and at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eya1, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5; and negative for the expression of CD133 and E-cadherin and at least one of Sox2, FGF4, hTert, Wnt-4, SIX2 or GATA-4.
2. The induced pluripotent stem cell of claim 1, wherein the induced pluripotent stem cell expresses TRA1-60, TRA1-81, SSEA3, SSEA4, and NANOG.
3. The induced pluripotent stem cell of claim 1, wherein the induced pluripotent stem cell is positive for alkaline phosphatase staining.
4. The induced pluripotent stem cell of claim 1, wherein the induced pluripotent stem cell differentiates into cells of an ectoderm, mesoderm, and endoderm lineages.
5. The induced pluripotent stem cell of claim 1, wherein the induced pluripotent stem cell differentiates into a hepatocyte cell, a hematoendothelial cell, and a definitive endoderm cell.
6. An induced pluripotent stem cell, as claimed in any one of the preceding claims, prepared by a method comprising the steps of:
   providing a human kidney-derived cell, wherein the human kidney-derived cell is positive for the expression of HLA-I and CD 44 and at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eya1, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5; and negative for the expression of CD133 and E-cadherin and at least one of Sox2, FGF4, hTert, Wnt-4, SIX2 or GATA-4
   transfecting the human kidney derived-cell with each one of a VSVg murine retrovirus expressing human transcription factor OCT4, a VSVg murine retrovirus expressing human transcription factor SOX2, a VSVg murine retrovirus expressing human transcription factor KLF4, and a VSVg murine retrovirus expressing human transcription factor c-MYC,
   culturing the transfected human kidney-derived cell,
   identifying an induced pluripotent stem cell,
   isolating the human kidney-derived IPS cell,
   subculturing the induced pluripotent stem cell, and

providing an induced pluripotent stem cell.

7. The method of claim 6, further transfecting the human kidney-derived cell with a VSVg murine retrovirus expressing human transcription factor p53-shRNA.
8. An induced pluripotent stem cell, as claimed in any one of the preceding claims, prepared by a method comprising the steps of:
   providing a human kidney-derived cell, transfecting the human kidney-derived cells with each one of an mRNA encoding a Oct-4 protein, an mRNA encoding a Sox2 protein, an mRNA encoding a Klf4 protein, an mRNA encoding a c-myc protein, and an mRNA encoding a Lin28 protein,
   culturing the transfected human kidney-derived iPS cell,
   identifying a induced pluripotent stem cell,
   isolating the induced pluripotent stem cell,
   subculturing the induced pluripotent stem cell, and
   providing an induced pluripotent stem cell.